Autologous hair follicle secretome treatment for androgenic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled single-site trial enrolls 60 adults with androgenic alopecia who are on a stable regimen of minoxidil and/or 5-alpha reductase inhibitors. Participants receive injections of autologous hair follicle-derived secretome or placebo at baseline and on days 30, 90, 180, 270 and 365, with each affected scalp quadrant receiving a vial diluted in saline and ~20 grid-pattern injections per quadrant. Outcomes include quantitative hair density and thickness measurements and patient-reported outcomes, and the product's proteomic profile is noted to contain higher concentrations of bioactive components than matched PRP. The protocol is designed to detect safety signals and clinical hair regrowth over a one-year treatment and follow-up period.

Why it matters

Who can join: the full rules

Inclusion Criteria

* SUBJECTS MUST BE ON A STABLE COURSE OF MINOXIDIL (ORAL OR TOPICAL) AND/OR 5-ALPHA REDUCTASE INHIBITORS. THEY MUST HAVE BEEN ON THE SAME 5-ALPHA REDUCTASE INHIBITOR FOR ≥12 MONTHS PRIOR TO BASELINE.
* FEMALE SUBJECTS MUST NOT BE ON HAIR GROWTH MEDICATIONS OR TOPICALS FOR ≥6 MONTHS PRIOR TO BASELINE.
* TESTOSTERONE REPLACEMENT THERAPY (TRT) IN ANY FORM (E.G. DEPO-, INJECTABLE, TOPICAL, PATCHES, NASAL GEL, ORAL, PELLET ETC.) IS ALLOWED AS LONG AS SUBJECT HAS BEEN ON A STABLE COURSE (IN THE OPINION OF THE INVESTIGATOR) OF TRT FOR ≥12 MONTHS.
* Biological sex: Male and Female (up to n=20 males and up to n=10 females will be in each arm for a total of up to n=40 males and up to n=20 females)
* Age: ≥18 - 65 years
* Subjects with Androgenic alopecia
* No intention to start new hair growth medications and no intention to change the dosage or usage of minoxidil or 5-alpha reductase inhibitors until the end of their participation in the trial.
* Competent and willing to provide written, informed consent to participate in all study activities.
* Willing and able to tolerate multiple injections of the study product.
* Must be able to attend all study related clinical visits.
* Willing to maintain the same hair style as at the Screening Visit for the duration of the study.
* Must be willing to have small (diameter similar to a pencil lead) UV (invisible) or red colored tattoo dots applied to scalp (up to 5) and touch up tattoos if necessary. UV tattoo dots only show under black light. Subjects will chose UV or red.

Exclusion Criteria

* Subjects with clinical diagnosis of alopecia areata or other non-androgenic forms of alopecia.
* Active skin disease (Psoriasis or severe seborrheic dermatitis) of the scalp
* Scalp infection
* Severe active systemic infection
* Cuts or abrasions on the scalp
* History of surgical hair restoration in the last 12 months.
* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers)
* History of systemic chemotherapy or radiation
* History of thyroid dysfunction
* History of autoimmune disorder (specifically Graves disease, Hashimoto thyroiditis, or systemic lupus erythematosus)
* Continuous/daily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.
* Use of any medications that potentially cause drug-induced hair loss (e.g., depo-testosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
* Known allergy or sensitivity to tattoo ink.
* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban; warfarin/coumarins)
* Significant tendency to develop keloids or hypertrophic scarring
* Subjects unable to communicate with the investigator and staff
* Any health condition that in the investigator's opinion should preclude participation in this study

Where it's running

• Ziering Medical
  West Hollywood, California, United States Recruiting

Study contacts

• Study coordinator: Lisa M Campbell, PhD
• Email: lisa@acorn.me
• Phone: 905-695-6956

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual treatment with KeraFactor and Revian LED for female pattern hair loss

  This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.

  Recruiting K. Kay Durairaj, MD, FACS, A Medical Corporation · Pasadena, California · NCT07810504

• Two hair supplements for men with androgenic alopecia

  This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.

  Recruiting at 6 sites Activ'inside · Rende, Cosenza and 5 other locations · NCT07806474

• Alopecia Areata: looking at ferroptosis markers in blood

  This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Cerrahpasa Mahallesi · NCT07733063

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• 2-Deoxy-D-ribose hydrogel versus 5% minoxidil for androgenetic alopecia

  This trial will test whether a once-daily topical 2‑Deoxy‑D‑ribose hydrogel is as effective and safe as 5% minoxidil for adults aged 18 to 50 with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07502976

• TH07 topical treatment for male pattern hair loss

  This trial will test whether a new daily topical spray called TH07 helps men aged 18–49 with male pattern hair loss grow more hair than standard minoxidil or a placebo over 24 weeks.

  Recruiting Phase 3 Triple Hair Inc · Vancouver, British Columbia · NCT07435012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.